	US 12,296,004 B2
	Recombinant virus with diminished latency and methods of using same
Jeffrey I. Cohen, Bethesda, MD (US); and Lesley Pesnicak, Stafford, VA (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The U.S.A., as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Mar. 11, 2022, as Appl. No. 17/692,540.
Application 17/692,540 is a division of application No. 16/195,247, filed on Nov. 19, 2018, granted, now 11,305,009.
Application 16/195,247 is a division of application No. 12/514,011, granted, now 10,166,285, issued on Jan. 1, 2019, previously published as PCT/US2007/084331, filed on Nov. 9, 2007.
Claims priority of provisional application 60/857,766, filed on Nov. 9, 2006.
Prior Publication US 2022/0193227 A1, Jun. 23, 2022
Int. Cl. A61K 39/25 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/25 (2013.01) [A61K 39/12 (2013.01); A61K 39/245 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5254 (2013.01); C12N 2710/16022 (2013.01); C12N 2710/16722 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/16743 (2013.01); C12N 2710/16761 (2013.01)]

13 Claims

1. A method for making an attenuated live virus having an impaired ability to establish latency, comprising:

introducing a recombinant virus comprising all or a portion of a herpes virus genome into a host cell to produce an amount of the recombinant virus suitable for a vaccine, wherein the recombinant virus genome comprises a promoter for a latency gene or transcript that is altered or modified, and the gene or transcript is expressed from the recombinant virus genome during viral replication; and

recovering the recombinant virus from the host cell.